Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. International most cancers statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2024;74(3):229–63.
Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A. Molecular panorama of remedy resistance in prostate most cancers: a pre-clinical and bioinformatics evaluation for medical translation. Most cancers Metastasis Rev. 2024;43(1):229–60.
Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi Ok, Hashemi M, et al. Molecular panorama of LncRNAs in prostate most cancers: A give attention to pathways and therapeutic targets for intervention. J Exp Clin Most cancers Res. 2022;41(1):214.
Mirzaei S, Paskeh MDA, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, et al. Reworking development factor-beta (TGF-beta) in prostate most cancers: A twin operate mediator? Int J Biol Macromol. 2022;206:435–52.
Chen H, Pang B, Zhou C, Han M, Gong J, Li Y, et al. Prostate cancer-derived small extracellular vesicle proteins: the hope in analysis, prognosis, and therapeutics. J Nanobiotechnol. 2023;21(1):480.
Henrich SE, McMahon KM, Plebanek MP, Calvert AE, Feliciano TJ, Parrish S, et al. Prostate most cancers extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent method. J Extracell Vesicles. 2020;10(2):e12042.
Giovannelli P, Di Donato M, Galasso G, Monaco A, Licitra F, Perillo B, et al. Communication between cells: exosomes as a supply system in prostate most cancers. Cell Commun Sign. 2021;19(1):110.
Chhabra Y, Weeraratna AT. Fibroblasts in most cancers: unity in heterogeneity. Cell. 2023;186(8):1580–609.
Mehla Ok, Singh PK. Metabolic regulation of macrophage polarization in most cancers. Tendencies Most cancers. 2019;5(12):822–34.
Hu A, Solar L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic development in most cancers. Sign Transduct Goal Ther. 2024;9(1):68.
Huang D, Rao D, Xi X, Zhang Z, Zhong T. Software of extracellular vesicles proteins in most cancers analysis. Entrance Cell Dev Biol. 2022;10:1007360.
Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, et al. Colorectal cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages. Adv Sci (Weinh). 2022;9(9):2102620.
Seibold T, Waldenmaier M, Seufferlein T, Eiseler T. Small extracellular vesicles and metastasis-blame the messenger. Cancers (Basel). 2021;13(17).
Zhu Z, Zhou Y, Li H, Xu W, Wang T, Liu J, et al. Analysis developments and hotspots in prostate most cancers related exosome: a bibliometric evaluation. Entrance Oncol. 2023;13:1270104.
Vardaki I, Corn P, Gentile E, Track JH, Madan N, Hoang A, et al. Radium-223 therapy will increase immune checkpoint expression in extracellular vesicles from the metastatic prostate most cancers bone microenvironment. Clin Most cancers Res. 2021;27(11):3253–64.
Kalluri R, LeBleu VS. The biology, operate, and biomedical functions of exosomes. Science. 2020;367(6478).
Ma Q, Liang M, Wu Y, Dou C, Xu J, Dong S, et al. Small extracellular vesicles ship osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic area of interest. J Extracell Vesicles. 2021;10(4):e12068.
Pang B, Wang Q, Chen H, Liu Z, Han M, Gong J, et al. Proteomic identification of small extracellular vesicle proteins LAMB1 and histone H4 for prostate most cancers analysis and danger stratification. Adv Sci (Weinh). 2024;11(23):e2402509.
DeRita RM, Sayeed A, Garcia V, Krishn SR, Shields CD, Sarker S, et al. Tumor-derived extracellular vesicles require beta1 integrins to advertise anchorage-independent development. iScience. 2019;14:199–209.
Ramirez-Garrastacho M, Bajo-Santos C, Line A, Martens-Uzunova ES, de la Fuente JM, Moros M, et al. Extracellular vesicles as a supply of prostate most cancers biomarkers in liquid biopsies: a decade of analysis. Br J Most cancers. 2022;126(3):331–50.
Inder KL, Ruelcke JE, Petelin L, Moon H, Choi E, Rae J, et al. Cavin-1/PTRF alters prostate most cancers cell-derived extracellular vesicle content material and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation. J Extracell Vesicles. 2014;3.
Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug supply enhances the cytotoxicity of Paclitaxel in autologous prostate most cancers cells. J Management Launch. 2015;220(Pt B):727–37.
Han Q, Xie QR, Li F, Cheng Y, Wu T, Zhang Y, et al. Focused Inhibition of SIRT6 by way of engineered exosomes impairs tumorigenesis and metastasis in prostate most cancers. Theranostics. 2021;11(13):6526–41.
Zhupanyn P, Ewe A, Buch T, Malek A, Rademacher P, Muller C, et al. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced SiRNA supply in vitro and in vivo. J Management Launch. 2020;319:63–76.
Rezaeian A, Khatami F, Heidari Keshel S, Akbari MR, Mirzaei A, Gholami Ok, et al. The impact of mesenchymal stem cells-derived exosomes on the prostate, bladder, and renal most cancers cell strains. Sci Rep. 2022;12(1):20924.
Valiunas V, Gordon C, Valiuniene L, Devine D, Lin RZ, Cohen IS, et al. Intercellular supply of therapeutic oligonucleotides. J Drug Deliv Sci Technol. 2022;72.
Lai JJ, Chau ZL, Chen SY, Hill JJ, Korpany KV, Liang NW, et al. Exosome processing and characterization approaches for analysis and know-how improvement. Adv Sci (Weinh). 2022;9(15):e2103222.
Ullah A, Huang Y, Zhao Ok, Hua Y, Ullah S, Rahman MU, et al. Traits and potential medical functions of the extracellular vesicles of human pathogenic fungi. BMC Microbiol. 2023;23(1):227.
Zhou B, Xu Ok, Zheng X, Chen T, Wang J, Track Y, et al. Software of exosomes as liquid biopsy in medical analysis. Sign Transduct Goal Ther. 2020;5(1):144.
Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21(4):575–81.
Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication within the tumor microenvironment contributes to hepatocellular carcinoma improvement and development. J Hematol Oncol. 2019;12(1):53.
Ariotti N, Wu Y, Okano S, Gambin Y, Follett J, Rae J, et al. An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate most cancers cells. Autophagy. 2021;17(9):2200–16.
Datta A, Kim H, McGee L, Johnson AE, Talwar S, Marugan J, et al. Excessive-throughput screening recognized selective inhibitors of exosome biogenesis and secretion: a drug repurposing technique for superior most cancers. Sci Rep. 2018;8(1):8161.
Hilgemann DW, Lin MJ, Fantastic M, Deisl C. On the existence of endocytosis pushed by membrane part separations. Biochim Biophys Acta Biomembr. 2020;1862(1):183007.
Liu XM, Ma L, Schekman R. Selective sorting of MicroRNAs into exosomes by phase-separated YBX1 condensates. Elife. 2021;10.
Kalluri R, McAndrews KM. The position of extracellular vesicles in most cancers. Cell. 2023;186(8):1610–26.
Zhang Q, Jeppesen DK, Higginbotham JN, Graves-Deal R, Trinh VQ, Ramirez MA, et al. Supermeres are practical extracellular nanoparticles replete with illness biomarkers and therapeutic targets. Nat Cell Biol. 2021;23(12):1240–54.
Huang D, Solar G, Hao X, He X, Zheng Z, Chen C, et al. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells speed up leukemia development. J Clin Make investments. 2021;131(1).
Fafian-Labora JA, Rodriguez-Navarro JA, O’Loghlen A. Small extracellular vesicles have GST exercise and ameliorate senescence-related tissue harm. Cell Metab. 2020;32(1):71–86. e5.
Jung D, Shin S, Kang SM, Jung I, Ryu S, Noh S, et al. Reprogramming of T cell-derived small extracellular vesicles utilizing IL2 floor engineering induces potent anti-cancer results by means of MiRNA supply. J Extracell Vesicles. 2022;11(12):e12287.
Wang X, Xu F, Kou H, Zheng Y, Yang J, Xu Z, et al. Stromal cell-derived small extracellular vesicles improve radioresistance of prostate most cancers cells by way of interleukin-8-induced autophagy. J Extracell Vesicles. 2023;12(7):e12342.
Guan H, Peng R, Fang F, Mao L, Chen Z, Yang S, et al. Tumor-associated macrophages promote prostate most cancers development by way of exosome-mediated miR-95 switch. J Cell Physiol. 2020;235(12):9729–42.
Yu L, Sui B, Fan W, Lei L, Zhou L, Yang L, et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. J Extracell Vesicles. 2021;10(3):e12056.
Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, et al. Prostate cancer-derived urine exosomes: a novel method to biomarkers for prostate most cancers. Br J Most cancers. 2009;100(10):1603–7.
Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, et al. Elevated PSA expression on prostate most cancers exosomes in in vitro situation and in most cancers sufferers. Most cancers Lett. 2017;403:318–29.
Choi WWY, Sanchez C, Li JJ, Dinarvand M, Adomat H, Ghaffari M, et al. Extracellular vesicles from organic fluids as potential markers in castration resistant prostate most cancers. J Most cancers Res Clin Oncol. 2023;149(8):4701–17.
Li T, Solar X, Chen L. Exosome circ_0044516 promotes prostate most cancers cell proliferation and metastasis as a possible biomarker. J Cell Biochem. 2020;121(3):2118–26.
Lee J, Kwon MH, Kim JA, Rhee WJ. Detection of exosome MiRNAs utilizing molecular beacons for diagnosing prostate most cancers. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S52–63.
Lazaro-Ibanez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A, et al. Completely different gDNA content material within the subpopulations of prostate most cancers extracellular vesicles: apoptotic our bodies, microvesicles, and exosomes. Prostate. 2014;74(14):1379–90.
Skotland T, Ekroos Ok, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate most cancers biomarkers. Eur J Most cancers. 2017;70:122–32.
Zhang C, Qin C, Dewanjee S, Bhattacharya H, Chakraborty P, Jha NK, et al. Tumor-derived small extracellular vesicles in most cancers invasion and metastasis: molecular mechanisms, and medical significance. Mol Most cancers. 2024;23(1):18.
Mohan V, Das A, Sagi I. Rising roles of ECM reworking processes in most cancers. Semin Most cancers Biol. 2020;62:192–200.
Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, et al. Stiff matrix induces exosome secretion to advertise tumour development. Nat Cell Biol. 2023;25(3):415–24.
Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, et al. Differentiation of tumour-promoting stromal myofibroblasts by most cancers exosomes. Oncogene. 2015;34(3):290–302.
McAtee CO, Sales space C, Elowsky C, Zhao L, Payne J, Fangman T, et al. Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling. Matrix Biol. 2019;78–79:165–79.
Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Ideas of extracellular matrix remodelling in tumour development and metastasis. Nat Commun. 2020;11(1):5120.
Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, et al. Exosomes secreted beneath hypoxia improve invasiveness and stemness of prostate most cancers cells by concentrating on adherens junction molecules. Mol Carcinog. 2015;54(7):554–65.
Prigol AN, Rode MP, Silva AH, Cisilotto J, Creczynski-Pasa TB. Professional-angiogenic impact of PC-3 exosomes in endothelial cells in vitro. Cell Sign. 2021;87:110126.
Luo JQ, Yang TW, Wu J, Lai HH, Zou LB, Chen WB, et al. Exosomal PGAM1 promotes prostate most cancers angiogenesis and metastasis by interacting with ACTG1. Cell Demise Dis. 2023;14(8):502.
Krishn SR, Salem I, Quaglia F, Naranjo NM, Agarwal E, Liu Q, et al. The Αvβ6 integrin in most cancers cell-derived small extracellular vesicles enhances angiogenesis. J Extracell Vesicles. 2020;9(1):1763594.
Elaimy AL, Mercurio AM. Convergence of VEGF and YAP/TAZ signaling: implications for angiogenesis and most cancers biology. Sci Sign. 2018;11(552).
Xie M, Yu T, Jing X, Ma L, Fan Y, Yang F, et al. Exosomal circSHKBP1 promotes gastric most cancers development by way of regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. Mol Most cancers. 2020;19(1):112.
Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular carcinoma-derived Exosomal miRNA-21 contributes to tumor development by changing hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Most cancers Res. 2018;37(1):324.
Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A. Most cancers exosomes set off mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 2015;6(2):715–31.
Pudova E, Kobelyatskaya A, Katunina I, Snezhkina A, Nyushko Ok, Fedorova M, et al. Docetaxel resistance in castration-resistant prostate most cancers: transcriptomic determinants and the impact of inhibiting Wnt/beta-catenin signaling by XAV939. Int J Mol Sci. 2022;23(21).
Zhu S, Ni Y, Solar G, Wang Z, Chen J, Zhang X, et al. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate most cancers sufferers: affiliation with affected person consequence beneath abiraterone. Most cancers Med. 2021;10(18):6282–90.
Guan H, Mao L, Wang J, Wang S, Yang S, Wu H, et al. Exosomal RNF157 mRNA from prostate most cancers cells contributes to M2 macrophage polarization by means of destabilizing HDAC1. Entrance Oncol. 2022;12:1021270.
Liu Y, Yang C, Chen S, Liu W, Liang J, He S, et al. Most cancers-derived Exosomal miR-375 targets DIP2C and promotes osteoblastic metastasis and prostate most cancers development by regulating the Wnt signaling pathway. Most cancers Gene Ther. 2023;30(3):437–49.
Gan J, Liu S, Zhang Y, He L, Bai L, Liao R, et al. MicroRNA-375 is a therapeutic goal for castration-resistant prostate most cancers by means of the PTPN4/STAT3 axis. Exp Mol Med. 2022;54(8):1290–305.
Zeng F, Zhao C, Wang R, Ren L, Qiu H, Zou Z, et al. Antagonizing Exosomal miR-18a-5p derived from prostate most cancers cells ameliorates metastasis-induced osteoblastic lesions by concentrating on Hist1h2bc and activating Wnt/beta-catenin pathway. Genes Dis. 2023;10(4):1626–40.
Wang S, Du P, Cao Y, Ma J, Yang X, Yu Z, et al. Most cancers related fibroblasts secreted Exosomal miR-1290 contributes to prostate most cancers cell development and metastasis by way of concentrating on GSK3beta. Cell Demise Discov. 2022;8(1):371.
Huang G, Jiang Z, Zhu W, Wu Z. Exosomal circKDM4A induces CUL4B to advertise prostate most cancers cell malignancy in a mir-338-3p-dependent method. Biochem Genet. 2023;61(1):390–409.
Yang Z, Chen JQ, Liu TJ, Chen YL, Ma ZK, Fan YZ, et al. Flattening AR promotes osteoblasts to recruit prostate most cancers cells by altering Exosomal circ-DHPS/miR-214-3p/CCL5 pathway. Asian J Androl. 2023;26(2):195–204.
Zhang G, Liu Y, Yang J, Wang H, Xing Z. Inhibition of circ_0081234 reduces prostate most cancers tumor development and metastasis by way of the miR-1/MAP 3 K1 axis. J Gene Med. 2022;24(8):e3376.
Ding L, Zheng Q, Lin Y, Wang R, Wang H, Luo W, et al. Exosome-derived circTFDP2 promotes prostate most cancers development by stopping PARP1 from caspase-3-dependent cleavage. Clin Transl Med. 2023;13(1):e1156.
Ahadi A, Brennan S, Kennedy PJ, Hutvagner G, Tran N. Lengthy non-coding RNAs harboring MiRNA seed areas are enriched in prostate most cancers exosomes. Sci Rep. 2016;6:24922.
Jiang Y, Zhao H, Chen Y, Li Ok, Li T, Chen J, et al. Exosomal lengthy noncoding RNA HOXD-AS1 promotes prostate most cancers metastasis by way of miR-361-5p/FOXM1 axis. Cell Demise Dis. 2021;12(12):1129.
Mo C, Huang B, Zhuang J, Jiang S, Guo S, Mao X. LncRNA nuclear-enriched ample transcript 1 shuttled by prostate most cancers cells-secreted exosomes initiates osteoblastic phenotypes within the bone metastatic microenvironment by way of miR-205-5p/runt-related transcription issue 2/splicing issue proline- and glutamine-rich/polypyrimidine tract-binding protein 2 axis. Clin Transl Med. 2021;11(8):e493.
Li Q, Hu J, Shi Y, Xiao M, Bi T, Wang C, et al. Exosomal lncAY927529 enhances prostate most cancers cell proliferation and invasion by means of regulating bone microenvironment. Cell Cycle. 2021;20(23):2531–46.
Rauschenberger L, Staar D, Thom Ok, Scharf C, Venz S, Homuth G, et al. Exosomal particles secreted by prostate most cancers cells are potent mRNA and protein automobiles for the interference of tumor and tumor atmosphere. Prostate. 2016;76(4):409–24.
Hakulinen J, Sankkila L, Sugiyama N, Lehti Ok, Keski-Oja J. Secretion of energetic membrane sort 1 matrix metalloproteinase (MMP-14) into extracellular area in microvesicular exosomes. J Cell Biochem. 2008;105(5):1211–8.
Deep G, Jain A, Kumar A, Agarwal C, Kim S, Leevy WM, et al. Exosomes secreted by prostate most cancers cells beneath hypoxia promote matrix metalloproteinases exercise at pre-metastatic niches. Mol Carcinog. 2020;59(3):323–32.
Huertas-Larez R, Munoz-Moreno L, Recio-Aldavero J, Roman ID, Arenas MI, Blasco A, et al. Induction of extra aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate most cancers sufferers. Int J Most cancers. 2023;153:1829–41.
Liu P, Wang W, Wang F, Fan J, Guo J, Wu T, et al. Alterations of plasma Exosomal proteins and motabolies are related to the development of castration-resistant prostate most cancers. J Transl Med. 2023;21(1):40.
Gaballa R, Ali HEA, Mahmoud MO, Rhim JS, Ali HI, Salem HF, et al. Exosomes-mediated switch of itga2 promotes migration and invasion of prostate most cancers cells by inducing epithelial-mesenchymal transition. Cancers (Basel). 2020;12(8).
Lin CJ, Yun EJ, Lo UG, Tai YL, Deng S, Hernandez E, et al. The paracrine induction of prostate most cancers development by caveolin-1. Cell Demise Dis. 2019;10(11):834.
Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, et al. RelB enhances prostate most cancers development: implications for the position of the nuclear factor-kappaB various pathway in tumorigenicity. Most cancers Res. 2009;69(8):3267–71.
Li W, Xu J, Cheng L, Zhao C, Zhang L, Shao Q, et al. RelB promotes the migration and invasion of prostate most cancers DU145 cells by way of Exosomal ICAM1 in vitro. Cell Sign. 2022;91:110221.
Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, et al. p300/CBP Inhibition enhances the efficacy of programmed death-ligand 1 Blockade therapy in prostate most cancers. Oncogene. 2020;39(19):3939–51.
Lin S, Zhou S, Yuan T. The sugar-coated bullets of most cancers: Tumor-derived exosome floor glycosylation from fundamental information to functions. Clin Transl Med. 2020;10(6):e204.
Hung ME, Leonard JN. Stabilization of exosome-targeting peptides by way of engineered glycosylation. J Biol Chem. 2015;290(13):8166–72.
Vermassen T, D’Herde Ok, Jacobus D, Van Praet C, Poelaert F, Lumen N, et al. Launch of urinary extracellular vesicles in prostate most cancers is related to altered urinary N-glycosylation profile. J Clin Pathol. 2017;70(10):838–46.
Liu T, Mendes DE, Berkman CE. Practical prostate-specific membrane antigen is enriched in exosomes from prostate most cancers cells. Int J Oncol. 2014;44(3):918–22.
Kondo Ok, Harada Y, Nakano M, Suzuki T, Fukushige T, Hanzawa Ok, et al. Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung most cancers cells. J Biol Chem. 2022;298(6):101950.
Flemming JP, Hill BL, Haque MW, Raad J, Bonder CS, Harshyne LA, et al. miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas. J Extracell Vesicles. 2020;9(1):1790159.
Kyuno D, Zhao Ok, Schnolzer M, Provaznik J, Hackert T, Zoller M. Claudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells. Int J Most cancers. 2019;145(8):2182–200.
Mariscal J, Vagner T, Kim M, Zhou B, Chin A, Zandian M, et al. Complete palmitoyl-proteomic evaluation identifies distinct protein signatures for giant and small cancer-derived extracellular vesicles. J Extracell Vesicles. 2020;9(1):1764192.
Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen Ok, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects towards prostate most cancers tumorigenesis. Nat Commun. 2021;12(1):1812.
Wen D, Hu M, Guo W, Wu J, Wu Y. Multi-SUMOylation of NAC1 is crucial for the expansion of prostate most cancers cells. Biochem Biophys Res Commun. 2023;641:148–54.
Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez-Hernandez D, Vazquez J, Martin-Cofreces N, et al. Sumoylated hnRNPA2B1 controls the sorting of MiRNAs into exosomes by means of binding to particular motifs. Nat Commun. 2013;4:2980.
Wang W, Kong P, Feng Ok, Liu C, Gong X, Solar T, et al. Exosomal miR-222-3p contributes to castration-resistant prostate most cancers by activating mTOR signaling. Most cancers Sci. 2023;114:4252–69.
Wang Y, Fang YX, Dong B, Du X, Wang J, Wang X, et al. Discovery of extracellular vesicles derived miR-181a-5p in affected person’s serum as an indicator for bone-metastatic prostate most cancers. Theranostics. 2021;11(2):878–92.
Wang J, Du X, Wang X, Xiao H, Jing N, Xue W, et al. Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis. Most cancers Lett. 2022;526:76–90.
Zheng Y, Li JX, Chen CJ, Lin ZY, Liu JX, Lin FJ. Extracellular vesicle-derived circ_SLC19A1 promotes prostate most cancers cell development and invasion by means of the miR-497/septin 2 pathway. Cell Biol Int. 2020;44(4):1037–45.
Gu P, Chen X, Xie R, Han J, Xie W, Wang B, et al. LncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate most cancers by way of recruiting WDR5. Mol Ther. 2017;25(8):1959–73.
Xu F, Wang X, Huang Y, Zhang X, Solar W, Du Y, et al. Prostate most cancers cell-derived Exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8(+) T cell. Cell Rep. 2023;42(11):113424.
Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, et al. TFAP2C-mediated LncRNA PCAT1 inhibits ferroptosis in Docetaxel-resistant prostate most cancers by means of c-Myc/miR-25-3p/SLC7A11 signaling. Entrance Oncol. 2022;12:862015.
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Rising phagocytosis checkpoints in most cancers immunotherapy. Sign Transduct Goal Ther. 2023;8(1):104.
Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, et al. Tumor exosomes expressing Fas ligand mediate CD8 + T-cell apoptosis. Blood Cells Mol Dis. 2005;35(2):169–73.
Lundholm M, Schroder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on pure killer cells and CD8 + T cells: mechanism of immune evasion. PLoS ONE. 2014;9(9):e108925.
Lu YC, Ho CH, Hong JH, Kuo MC, Liao YA, Jaw FS, et al. NKG2A and Circulating extracellular vesicles are key regulators of pure killer cell exercise in prostate most cancers after prostatectomy. Mol Oncol. 2023;17(8):1613–27.
Guo D, Chen Y, Wang S, Yu L, Shen Y, Zhong H, et al. Exosomes from heat-stressed tumour cells inhibit tumour development by changing regulatory T cells to Th17 cells by way of IL-6. Immunology. 2018;154(1):132–43.
Li D, Zhou X, Xu W, Chen Y, Mu C, Zhao X, et al. Prostate most cancers cells synergistically defend towards CD8(+) T cells by secreting Exosomal PD-L1. Most cancers Med. 2023;12(15):16405–15.
Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant immunosuppression of dendritic cell operate by prostate-cancer-derived exosomes. J Extracell Vesicles. 2017;6(1):1368823.
Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, et al. Shedding of endogenous MHC class I-related chain molecules A and B from totally different human tumor entities: heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17. Int J Most cancers. 2013;133(7):1557–66.
Namee NM, O’Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Most cancers. 2018;1870(2):123–36.
Peak TC, Panigrahi GK, Praharaj PP, Su Y, Shi L, Chyr J, et al. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate most cancers. Mol Carcinog. 2020;59(1):62–72.
Kumar A, Kumar P, Sharma M, Kim S, Singh S, Kridel SJ, et al. Position of extracellular vesicles secretion in Paclitaxel resistance of prostate most cancers cells. Most cancers Drug Resist. 2022;5(3):612–24.
Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q, et al. Exosomal MiRNAs in tumor microenvironment. J Exp Clin Most cancers Res. 2020;39(1):67.
Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, et al. Exosome-derived MicroRNAs contribute to prostate most cancers chemoresistance. Int J Oncol. 2016;49(2):838–46.
Chen B, Sang Y, Track X, Zhang D, Wang L, Zhao W, et al. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast most cancers cell proliferation and metastasis by means of concentrating on USP28. Theranostics. 2021;11(8):3932–47.
Cao Z, Xu L, Zhao S. Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate most cancers chemoresistance by means of p53. Biochem Biophys Res Commun. 2019;515(2):345–51.
Shan G, Gu J, Zhou D, Li L, Cheng W, Wang Y, et al. Most cancers-associated fibroblast-secreted Exosomal miR-423-5p promotes chemotherapy resistance in prostate most cancers by concentrating on GREM2 by means of the TGF-beta signaling pathway. Exp Mol Med. 2020;52(11):1809–22.
Fenner A. Prostate most cancers: Exosomal AR-V7 is a marker of hormonal remedy resistance. Nat Rev Urol. 2016;13(12):695.
Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, et al. The detection of androgen receptor splice variant 7 in plasma-derived Exosomal Rna strongly predicts resistance to hormonal remedy in metastatic prostate most cancers sufferers. Eur Urol. 2017;71(4):680–7.
Binzel DW, Guo S, Yin H, Lee TJ, Liu S, Shu D, et al. Rational design for managed launch of Dicer-substrate SiRNA harbored in phi29 pRNA-based nanoparticles. Mol Remedy Nucleic Acids. 2021;25:524–35.
Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, et al. Most cancers-associated fibroblasts in breast most cancers: challenges and alternatives. Most cancers Commun (Lond). 2022;42(5):401–34.
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate most cancers. Most cancers Cell. 2020;38(2):279–96. e9.
Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells within the tumor microenvironment: new findings and future views. Mol Most cancers. 2021;20(1):131.
Shephard AP, Giles P, Mbengue M, Alraies A, Spary LK, Kynaston H, et al. Stroma-derived extracellular vesicle mRNA signatures inform histological nature of prostate most cancers. J Extracell Vesicles. 2021;10(12):e12150.
Shelton M, Anene CA, Nsengimana J, Roberts W, Newton-Bishop J, Boyne JR. The position of CAF derived Exosomal MicroRNAs within the tumour microenvironment of melanoma. Biochim Biophys Acta Rev Most cancers. 2021;1875(1):188456.
Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and Exosomal MicroRNA: trafficking, sorting, and performance. Genomics Proteom Bioinf. 2015;13(1):17–24.
Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson Ok, et al. Pre-existing castration-resistant prostate cancer-like cells in main prostate most cancers promote resistance to hormonal remedy. Eur Urol. 2022;81(5):446–55.
Zhang Y, Zhao J, Ding M, Su Y, Cui D, Jiang C, et al. Lack of Exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation remedy contributes to prostate most cancers metastasis. J Exp Clin Most cancers Res. 2020;39(1):282.
Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, et al. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34(21):2690–9.
Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, et al. Tumor microenvironment derived exosomes pleiotropically modulate most cancers cell metabolism. Elife. 2016;5:e10250.
Stone L. Singling out the immune-suppressive TME in prostate most cancers. Nat Rev Urol. 2023;20(4):199.
Andersen LB, Norgaard M, Rasmussen M, Fredsoe J, Borre M, Ulhoi BP, et al. Immune cell analyses of the tumor microenvironment in prostate most cancers spotlight infiltrating regulatory T cells and macrophages as adversarial prognostic elements. J Pathol. 2021;255(2):155–65.
Wang C, Zhang Y, Gao WQ. The evolving position of immune cells in prostate most cancers. Most cancers Lett. 2022;525:9–21.
Guan han. Solar wenyan, Wang sheng, zhijun C. Mechanism of miR-374a encapsulation in M2 macrophage exosomes promotes malignant development of prostate most cancers. Journal of Bengbu Medical Faculty. 2023; 48(6):701– 11.
Gao F, Xu Q, Tang Z, Zhang N, Huang Y, Li Z, et al. Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate most cancers development by way of S100A9/circMID1/miR-506-3p/MID1. J Transl Med. 2022;20(1):346.
Nie W, Wu G, Zhang J, Huang LL, Ding J, Jiang A, et al. Responsive exosome nano-bioconjugates for synergistic most cancers remedy. Angew Chem Int Ed Engl. 2020;59(5):2018–22.
Huang X, Wu W, Jing D, Yang L, Guo H, Wang L, et al. Engineered exosome as focused LncRNA MEG3 supply automobiles for osteosarcoma remedy. J Management Launch. 2022;343:107–17.
Jung I, Shin S, Baek MC, Yea Ok. Modification of immune cell-derived exosomes for enhanced most cancers immunotherapy: present advances and therapeutic functions. Exp Mol Med. 2024;56(1):19–31.
Shi X, Solar J, Li H, Lin H, Xie W, Li J, et al. Antitumor efficacy of interferon-gamma-modified Exosomal vaccine in prostate most cancers. Prostate. 2020;80(11):811–23.
Luo ZW, Xia Ok, Liu YW, Liu JH, Rao SS, Hu XK, et al. Extracellular vesicles from Akkermansia muciniphila elicit antitumor immunity towards prostate most cancers by way of modulation of CD8(+) T cells and macrophages. Int J Nanomed. 2021;16:2949–63.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate most cancers screening with prostate-specific antigen (PSA) check: a scientific assessment and meta-analysis. BMJ. 2018;362:k3519.
Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, et al. Plasma-derived Exosomal survivin, a believable biomarker for early detection of prostate most cancers. PLoS ONE. 2012;7(10):e46737.
Kawakami Ok, Fujita Y, Matsuda Y, Arai T, Horie Ok, Kameyama Ok, et al. Gamma-glutamyltransferase exercise in exosomes as a possible marker for prostate most cancers. BMC Most cancers. 2017;17(1):316.
Qin X, Niu R, Tan Y, Huang Y, Ren W, Zhou W, et al. Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate most cancers metastasis by means of the RACK1 signaling axis. Biomark Res. 2024;12(1):138.
Ji J, Chen R, Zhao L, Xu Y, Cao Z, Xu H, et al. Circulating Exosomal mRNA profiling identifies novel signatures for the detection of prostate most cancers. Mol Most cancers. 2021;20(1):58.
Schneider L, Dansranjav T, Neumann E, Yan H, Pilatz A, Schuppe HC, et al. Submit-prostatic-massage urine exosomes of males with power prostatitis/power pelvic ache syndrome carry prostate-cancer-typical MicroRNAs and activate proto-oncogenes. Mol Oncol. 2023;17(3):445–68.
Barcelo M, Castells M, Bassas L, Vigues F, Larriba S. Semen MiRNAs contained in exosomes as non-invasive biomarkers for prostate most cancers analysis. Sci Rep. 2019;9(1):13772.
Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al. The identification of plasma Exosomal mir-423-3p as a possible predictive biomarker for prostate most cancers castration-resistance improvement by plasma Exosomal Mirna sequencing. Entrance Cell Dev Biol. 2020;8:602493.
Rode MP, Silva AH, Cisilotto J, Rosolen D, Creczynski-Pasa TB. miR-425-5p as an Exosomal biomarker for metastatic prostate most cancers. Cell Sign. 2021;87:110113.
Cruz-Burgos M, Cortes-Ramirez SA, Losada-Garcia A, Morales-Pacheco M, Martinez-Martinez E, Morales-Montor JG, et al. Unraveling the position of EV-derived mir-150-5p in prostate most cancers metastasis and its affiliation with high-grade Gleason scores: implications for analysis. Cancers (Basel). 2023;15(16).
Temilola DO, Wium M, Paccez J, Salukazana AS, Otu HH, Carbone GM, et al. Potential of MiRNAs in plasma extracellular vesicle for the stratification of prostate most cancers in a South African inhabitants. Cancers (Basel). 2023;15(15).
Lu Z, Hou J, Li X, Zhou J, Luo B, Liang S, et al. Exosome-derived MiRNAs as potential biomarkers for prostate bone metastasis. Int J Gen Med. 2022;15:5369–83.
Ashok G, Das R, Anbarasu A, Ramaiah S. Complete evaluation on the diagnostic position of circulatory exosome-based miR-92a-3p for osteoblastic metastases in prostate adenocarcinoma. J Mol Recognit. 2023;36(8):e3042.
Shin S, Park YH, Jung SH, Jang SH, Kim MY, Lee JY, et al. Urinary exosome MicroRNA signatures as a noninvasive prognostic biomarker for prostate most cancers. NPJ Genom Med. 2021;6(1):45.
Duijvesz D, Versluis CY, van der Fels CA, Vredenbregt-van den Berg MS, Leivo J, Peltola MT, et al. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate most cancers. Int J Most cancers. 2015;137(12):2869–78.
McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, et al. A potential adaptive utility trial to validate efficiency of a novel urine exosome gene expression assay to foretell high-grade prostate most cancers in sufferers with prostate-specific antigen 2-10ng/ml at preliminary biopsy. Eur Urol. 2018;74(6):731–8.
McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to foretell high-grade prostate most cancers at preliminary biopsy. JAMA Oncol. 2016;2(7):882–9.
Zhu S, Ni Y, Wang Z, Zhang X, Zhang Y, Zhao F, et al. Plasma Exosomal AKR1C3 mRNa expression is a predictive and prognostic biomarker in sufferers with metastatic castration-resistant prostate most cancers. Oncologist. 2022;27(11):e870–7.
Pudova EA, Kobelyatskaya AA, Katunina IV, Snezhkina AV, Fedorova MS, Guvatova ZG, et al. Dynamic profiling of Exosomal Micrornas in blood plasma of sufferers with castration-resistant prostate most cancers. Entrance Biosci (Schol Ed). 2022;14(2):15.
Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate most cancers. Eur Urol. 2015;67(1):33–41.
Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, et al. Prostate most cancers sheds the alphavbeta3 integrin in vivo by means of exosomes. Matrix Biol. 2019;77:41–57.
Singh A, Fedele C, Lu H, Nevalainen MT, Eager JH, Languino LR. Exosome-mediated switch of Αvβ3 integrin from tumorigenic to nontumorigenic cells promotes a migratory phenotype. Mol Most cancers Res. 2016;14(11):1136–46.
Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, et al. Prostate most cancers biomarker profiles in urinary sediments and exosomes. J Urol. 2014;191(4):1132–8.
Liang H, Wang X, Li F, Xie Y, Shen J, Wang X, et al. Label-free plasmonic metasensing of PSA and exosomes in serum for fast high-sensitivity analysis of early prostate most cancers. Biosens Bioelectron. 2023;235:115380.
Wu D, Yan J, Shen X, Solar Y, Thulin M, Cai Y, et al. Profiling floor proteins on particular person exosomes utilizing a proximity barcoding assay. Nat Commun. 2019;10(1):3854.
Li Q, Wang Y, Xue Y, Qiao L, Yu G, Liu Y, et al. Ultrasensitive evaluation of exosomes utilizing a 3D self-assembled nanostructured SiO2 microfluidic chip. ACS Appl Mater Interfaces. 2022;14(12):14693–702.
Kim J, Shim JS, Han BH, Kim HJ, Park J, Cho IJ, et al. Hydrogel-based hybridization chain response (HCR) for detection of urinary Exosomal MiRNAs as a diagnostic device of prostate most cancers. Biosens Bioelectron. 2021;192:113504.
Track J, Cho MH, Cho H, Track Y, Lee SW, Nam HC, et al. Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE. Nat Biotechnol. 2024.
Guo Q, Zhao C, Gao X, Ding L, Wang P, Ren Y, et al. One-minute iodine isotope labeling know-how allows noninvasive monitoring and quantification of extracellular vesicles in tumor lesions and intact animals. Mol Pharm. 2023;20(7):3672–82.
Liu Y, Li M, Liu H, Kang C, Wang C. Most cancers analysis utilizing label-free SERS-based exosome evaluation. Theranostics. 2024;14(5):1966–81.
Kim WH, Lee JU, Jeon MJ, Park KH, Sim SJ. Three-dimensional hierarchical plasmonic nano-architecture primarily based label-free surface-enhanced Raman spectroscopy detection of urinary Exosomal MiRNA for medical analysis of prostate most cancers. Biosens Bioelectron. 2022;205:114116.
Dong S, Wang Y, Liu Z, Zhang W, Yi Ok, Zhang X, et al. Beehive-inspired macroporous SERS probe for most cancers detection by means of capturing and analyzing exosomes in plasma. ACS Appl Mater Interfaces. 2020;12(4):5136–46.
Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–82.
Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in most cancers: alternatives and challenges. Ann Oncol. 2021;32(4):466–77.
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a brand new frontier of most cancers liquid biopsy. Mol Most cancers. 2022;21(1):56.
Li J, Wang J, Chen Z. Rising position of exosomes in most cancers remedy: progress and challenges. Mol Most cancers. 2025;24(1):13.
Dean I, Dzinic SH, Bernardo MM, Zou Y, Kimler V, Li X, et al. The secretion and organic operate of tumor suppressor Maspin as an exosome cargo protein. Oncotarget. 2017;8(5):8043–56.
Severic M, Ma G, Pereira SGT, Ruiz A, Cheung CCL, Al-Jamal WT. Genetically-engineered anti-PSMA exosome mimetics concentrating on superior prostate most cancers in vitro and in vivo. J Management Launch. 2021;330:101–10.
Alhasan AH, Patel PC, Choi CH, Mirkin CA. Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent MicroRNA regulation brokers. Small. 2014;10(1):186–92.
Pan S, Zhang Y, Huang M, Deng Z, Zhang A, Pei L, et al. Urinary exosomes-based engineered nanovectors for homologously focused chemo-chemodynamic prostate most cancers remedy by way of abrogating EGFR/AKT/NF-kB/IkB signaling. Biomaterials. 2021;275:120946.
Peng Y, Zhao M, Hu Y, Guo H, Zhang Y, Huang Y, et al. Blockade of exosome era by GW4869 inhibits the schooling of M2 macrophages in prostate most cancers. BMC Immunol. 2022;23(1):37.
Wang D, Wan Z, Yang Q, Chen J, Liu Y, Lu F, et al. Sonodynamical reversion of immunosuppressive microenvironment in prostate most cancers by way of engineered exosomes. Drug Deliv. 2022;29(1):702–13.
Lee JH, Track J, Kim IG, You G, Kim H, Ahn JH, et al. Exosome-mediated supply of reworking development factor-beta receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for mixture remedy of tumors. Acta Biomater. 2022;141:354–63.
Bu J, Jeong WJ, Jafari R, Kubiatowicz LJ, Nair A, Poellmann MJ, et al. Bimodal liquid biopsy for most cancers immunotherapy primarily based on peptide engineering and nanoscale evaluation. Biosens Bioelectron. 2022;213:114445.
Cha E, Fong L. Therapeutic vaccines for prostate most cancers. Curr Opin Mol Ther. 2010;12(1):77–85.
Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo Ok, Do L, Lombardo JR, et al. Exosome concentrating on of tumor antigens expressed by most cancers vaccines can enhance antigen immunogenicity and therapeutic efficacy. Most cancers Res. 2011;71(15):5235–44.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate most cancers. N Engl J Med. 2010;363(5):411–22.
Tan F, Li X, Wang Z, Li J, Shahzad Ok, Zheng J. Medical functions of stem cell-derived exosomes. Sign Transduct Goal Ther. 2024;9(1):17.
Tang J, Chen Y, Wang C, Xia Y, Yu T, Tang M, et al. The position of mesenchymal stem cells in most cancers and prospects for his or her use in most cancers therapeutics. MedComm (2020). 2024;5(8):e663.
Peak TC, Praharaj PP, Panigrahi GK, Doyle M, Su Y, Schlaepfer IR, et al. Exosomes secreted by placental stem cells selectively inhibit development of aggressive prostate most cancers cells. Biochem Biophys Res Commun. 2018;499(4):1004–10.
Vakhshiteh F, Atyabi F, Ostad SN. Mesenchymal stem cell exosomes: a two-edged sword in most cancers remedy. Int J Nanomed. 2019;14:2847–59.
Pakravan Ok, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, Ataei F, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis by means of modulating the mTOR/HIF-1alpha/VEGF signaling axis in breast most cancers cells. Cell Oncol (Dordr). 2017;40(5):457–70.
Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, et al. Complete proteomic evaluation of mesenchymal stem cell exosomes reveals modulation of angiogenesis by way of nuclear factor-KappaB signaling. Stem Cells. 2016;34(3):601–13.
Alcayaga-Miranda F, Gonzalez PL, Lopez-Verrilli A, Varas-Godoy M, Aguila-Diaz C, Contreras L, et al. Prostate tumor-induced angiogenesis is blocked by exosomes derived from menstrual stem cells by means of the Inhibition of reactive oxygen species. Oncotarget. 2016;7(28):44462–77.
Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by instantly concentrating on mucin 1. Most cancers Res. 2010;70(1):378–87.
Takahara Ok, Ii M, Inamoto T, Nakagawa T, Ibuki N, Yoshikawa Y, et al. MicroRNA-145 mediates the inhibitory impact of adipose tissue-derived stromal cells on prostate most cancers. Stem Cells Dev. 2016;25(17):1290–8.
Jiang S, Mo C, Guo S, Zhuang J, Huang B, Mao X. Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the development of prostate most cancers by means of suppression of RHPN2. J Exp Clin Most cancers Res. 2019;38(1):495.
Jiang S, Mo C, Guo S, Zhuang J, Huang B, Mao X, Correction. Human bone marrow mesenchymal stem cells-derived microRNA-205-containing exosomes impede the development of prostate most cancers by means of suppression of RHPN2. J Exp Clin Most cancers Res. 2022;41(1):206.
Kurniawati I, Liu MC, Hsieh CL, Do AD, Sung SY. Concentrating on castration-resistant prostate most cancers utilizing mesenchymal stem cell exosomes for therapeutic microRNA-let-7c supply. Entrance Biosci (Landmark Ed). 2022;27(9):256.
Jiang S, Chen H, He Ok, Wang J. Human bone marrow mesenchymal stem cells-derived exosomes attenuated prostate most cancers development by way of the miR-99b-5p/IGF1R axis. Bioengineered. 2022;13(2):2004–16.
Li C, Solar Z, Track Y, Zhang Y. Suppressive operate of bone marrow-derived mesenchymal stem cell-derived Exosomal microRNA-187 in prostate most cancers. Most cancers Biol Ther. 2022;23(1):1–14.
Wu X, Zeng Z, Peng Ok, Ren D, Zhang L. Regulatory mechanism of DHRS2-modified human umbilical twine mesenchymal stem cells-derived exosomes in prostate most cancers cell proliferation and apoptosis. Tissue Cell. 2023;82:102078.
Zhao Q, Hai B, Kelly J, Wu S, Liu F. Extracellular vesicle mimics produced from iPS cell-derived mesenchymal stem cells enhance the therapy of metastatic prostate most cancers. Stem Cell Res Ther. 2021;12(1):29.
Yang S, Liang X, Track J, Li C, Liu A, Luo Y, et al. A novel therapeutic method for inflammatory bowel illness by exosomes derived from human umbilical twine mesenchymal stem cells to restore intestinal barrier by way of TSG-6. Stem Cell Res Ther. 2021;12(1):315.
Padinharayil H, Varghese J, Wilson C, George A. Mesenchymal stem cell-derived exosomes: traits and functions in illness pathology and administration. Life Sci. 2024;342:122542.
Tian Y, Guo X, Cheng J, Wang P. Exosomes derived from mesenchymal stem cells loaded with Annexin A2 scale back the polarization of M2 macrophages to inhibit the expansion of prostate most cancers cells in nude mice. J Cell Mol Immunol. 2023;39(2):109–16.
Wang S, Khan A, Huang R, Ye S, Di Ok, Xiong T, et al. Latest advances in single extracellular vesicle detection strategies. Biosens Bioelectron. 2020;154:112056.
Lim M, Shin H, Jeong H, Kwon Y, Kim M, Lee J, et al. Analysis of prostate most cancers metastasis by way of extracellular vesicles remoted utilizing two-phase interface as membrane-less filter. Small. 2024;20(52):2404846.
Wolf J, Rasmussen DK, Solar YJ, Vu JT, Wang E, Espinosa C, et al. Liquid-biopsy proteomics mixed with AI identifies mobile drivers of eye growing older and illness in vivo. Cell. 2023;186(22):4868–84. e12.
Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and analysis methods of pancreatic most cancers: a complete assessment. Most cancers Commun (Lond). 2021;41(12):1257–74.
Choi JY, Park S, Shim JS, Park HJ, Kuh SU, Jeong Y, et al. Explainable synthetic intelligence-driven prostate most cancers screening utilizing Exosomal multi-marker primarily based dual-gate FET biosensor. Biosens Bioelectron. 2025;267:116773.
Sych T, Schlegel J, Barriga HMG, Ojansivu M, Hanke L, Weber F, et al. Excessive-throughput measurement of the content material and properties of nano-sized bioparticles with single-particle profiler. Nat Biotechnol. 2024;42(4):587–90.
Correction to. Minimal data for research of extracellular vesicles (MISEV2023): From fundamental to superior approaches. J Extracell Vesicles. 2024;13(5):e12451.
Witwer KW, Goberdhan DC, O’Driscoll L, Thery C, Welsh JA, Blenkiron C, et al. Updating MISEV: evolving the minimal necessities for research of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182.
